

Cover Story
After a courtroom victory against Amgen Inc. this summer, the last of the obstacles was removed for the first biosimilar agent—a white blood cell growth factor—to enter the U.S. market.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Drugs & Targets


Trending Stories
- Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say - With Anthony Letai’s appointment, NCI is now under new leadership—just in time for a shutdown
- Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature” - Anthony Letai sworn in as 18th NCI director
- Bhattacharya: New grant review criterion is “not political”
- Population-based cancer surveillance is a national treasure at risk